Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJasper Brugts MD PhD

About this trial

The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4 pillars of guideline directed medical therapy (GDMT) in HFrEF patients will help to further improve the implementation of GDMT.

Data will be used from the national HF registry in the Netherlands. Two groups will be studied, one where the HCP receives the mirror information on GDMT and one where both the patient and the HCP receive the mirror information on GDMT. GDMT or the 4 pillars treatment is standard of care as recommended by the ESC HF guidelines, indicated for all HFrEF patients. The project is a quality of care registry and health care evaluation to optimize adherence to the HF guidelines.

Eligibility criteria

Qualifiers

Written informed consent

Age ≥18 years

Diagnosis of HFrEF according to ESC HF guidelines (EF <40%)

Participant is willing to participate for 1 years of follow-up for standard of care at the outpatient clinic of the participating hospital and the local investigator follows the patients for the time frame of 1 years on reported endpoints.

Disqualifiers

An expected life expectancy less than 1 year due to other comorbidities according to the treating physician

A major CV event (e.g. disabling stroke, myocardial infarction, open heart surgery) within 3 months of enrollment, if likely to interfere with GDMT titration or regular follow-up.

Advanced or Endstage Heart Failure stage in which advanced HF treatment with an LVAD or heart transplant is anticipated within 6 months after the baseline visit.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,500 Participants
are grouped into 2 trial groups

Locations

This trial has no locations

Sponsors and collaborators

Jasper Brugts MD PhD

Lead sponsor

Erasmus Medical Center

Sponsor institution

Dutch Heart Foundation

Collaborator